From the Food and Drug Administration.
Schwetz
B A
BA
Food and Drug Administration, USA.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000009:adverse effects*; D006801:Humans; D007255:Information Services; D015474:Isotretinoin / Q000009:adverse effects*; D000077289:Letrozole; D019804:Mesalamine / Q000008:administration & dosage*; D009570:Nitriles / Q000627:therapeutic use*; D012306:Risk; D013488:Suppositories; D014230:Triazoles / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents; D003879:Dermatologic Agents; D009570:Nitriles; D013488:Suppositories; D014230:Triazoles; D019804:Mesalamine; D000077289:Letrozole; D015474:Isotretinoin